JP2019518460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518460A5 JP2019518460A5 JP2018565336A JP2018565336A JP2019518460A5 JP 2019518460 A5 JP2019518460 A5 JP 2019518460A5 JP 2018565336 A JP2018565336 A JP 2018565336A JP 2018565336 A JP2018565336 A JP 2018565336A JP 2019518460 A5 JP2019518460 A5 JP 2019518460A5
- Authority
- JP
- Japan
- Prior art keywords
- engineered
- composition
- regulatory
- cell
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022021158A JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662351104P | 2016-06-16 | 2016-06-16 | |
| US62/351,104 | 2016-06-16 | ||
| PCT/US2017/037794 WO2017218850A1 (en) | 2016-06-16 | 2017-06-15 | Engineered treg cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022021158A Division JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518460A JP2019518460A (ja) | 2019-07-04 |
| JP2019518460A5 true JP2019518460A5 (enExample) | 2020-07-27 |
Family
ID=60663377
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565336A Withdrawn JP2019518460A (ja) | 2016-06-16 | 2017-06-15 | 操作されたＴｒｅｇ細胞 |
| JP2022021158A Pending JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022021158A Pending JP2022058995A (ja) | 2016-06-16 | 2022-02-15 | 操作されたＴｒｅｇ細胞 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190322983A1 (enExample) |
| EP (1) | EP3472305A4 (enExample) |
| JP (2) | JP2019518460A (enExample) |
| CN (1) | CN109415698A (enExample) |
| AU (1) | AU2017285319A1 (enExample) |
| CA (1) | CA3027546A1 (enExample) |
| MA (1) | MA45498A (enExample) |
| WO (1) | WO2017218850A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018069927A1 (en) * | 2016-10-10 | 2018-04-19 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| GB201714718D0 (en) | 2017-09-13 | 2017-10-25 | Autolus Ltd | Cell |
| US20210017248A1 (en) * | 2018-03-16 | 2021-01-21 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| CA3105953A1 (en) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions and uses thereof |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| WO2020102503A2 (en) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Fusosome compositions for t cell delivery |
| JP7642548B2 (ja) * | 2019-02-01 | 2025-03-10 | ケーエスキュー セラピューティクス， インコーポレイテッド | 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法 |
| WO2021007396A2 (en) * | 2019-07-09 | 2021-01-14 | The Children's Mercy Hospital | Engineered regulatory t cells |
| WO2021154882A1 (en) * | 2020-01-27 | 2021-08-05 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Hdac6-inhibited human regulatory t cells |
| US20230138428A1 (en) | 2020-02-25 | 2023-05-04 | Quell Therapeutics Limited | Chimeric receptors for use in engineered cells |
| US12668777B2 (en) | 2020-08-05 | 2026-06-30 | Augusta University Research Institute, Inc. | Chimeric antigen receptor T cells and methods of use thereof |
| GB202102637D0 (en) | 2021-02-24 | 2021-04-07 | Quell Therapeutics Ltd | Engineered regulatory t cell |
| JP2024532963A (ja) | 2021-04-08 | 2024-09-11 | サナ バイオテクノロジー，インコーポレイテッド | Ｃｄ８特異的抗体コンストラクト及びその組成物 |
| AU2022372894A1 (en) * | 2021-10-20 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Compositions targeting bcma and methods of use thereof |
| JP2026507781A (ja) | 2023-01-23 | 2026-03-06 | メディツィニシェ ホゥーシュル ハノーファー | キメラ抗原受容体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| CN120787258A (zh) | 2023-02-07 | 2025-10-14 | 圭尔医疗有限公司 | Treg细胞培养方法 |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194605A1 (en) | 2023-03-17 | 2024-09-26 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| US20260176598A1 (en) | 2024-07-04 | 2026-06-25 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235873B1 (en) * | 1999-07-31 | 2001-05-22 | The Rockefeller University | Constitutively active transcription factors and their uses for identifying modulators of activity including dysproliferative cellular changes |
| JP2010531138A (ja) * | 2007-06-13 | 2010-09-24 | ラ ホヤ インスティテュート フォア アラージー アンド イムノロジー | 制御性ｔ細胞ならびに同製造および使用方法 |
| US8658159B2 (en) * | 2008-06-30 | 2014-02-25 | Versitech Limited | Method to induce and expand therapeutic alloantigen-specific human regulatory T cells in large-scale |
| WO2015188141A2 (en) * | 2014-06-06 | 2015-12-10 | Memorial Sloan-Kettering Cancer Ceneter | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| EP3158064A1 (en) * | 2014-06-17 | 2017-04-26 | Cellectis | Cd123 specific multi-chain chimeric antigen receptor |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
-
2017
- 2017-06-15 MA MA045498A patent/MA45498A/fr unknown
- 2017-06-15 CA CA3027546A patent/CA3027546A1/en active Pending
- 2017-06-15 WO PCT/US2017/037794 patent/WO2017218850A1/en not_active Ceased
- 2017-06-15 AU AU2017285319A patent/AU2017285319A1/en not_active Abandoned
- 2017-06-15 JP JP2018565336A patent/JP2019518460A/ja not_active Withdrawn
- 2017-06-15 EP EP17814140.4A patent/EP3472305A4/en not_active Withdrawn
- 2017-06-15 US US16/310,668 patent/US20190322983A1/en not_active Abandoned
- 2017-06-15 CN CN201780037655.8A patent/CN109415698A/zh active Pending
-
2022
- 2022-02-15 JP JP2022021158A patent/JP2022058995A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chatzileontiadou et al. | The many faces of CD4+ T cells: immunological and structural characteristics | |
| Lopes et al. | The immune microenvironment in multiple myeloma: friend or foe? | |
| Arroyo Hornero et al. | CD70 expression determines the therapeutic efficacy of expanded human regulatory T cells | |
| Takamura et al. | Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors | |
| Titov et al. | Knowns and unknowns about CAR-T cell dysfunction | |
| Trzonkowski et al. | Ex vivo expansion of CD4+ CD25+ T regulatory cells for immunosuppressive therapy | |
| Dwyer et al. | Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype | |
| Wang et al. | Expression of GARP selectively identifies activated human FOXP3+ regulatory T cells | |
| Chen et al. | TNF-α: an activator of CD4+ FoxP3+ TNFR2+ regulatory T cells | |
| Sierra et al. | Tumor-experienced human NK cells express high levels of PD-L1 and inhibit CD8+ T cell proliferation | |
| Rudak et al. | MAIT cell-mediated cytotoxicity: Roles in host defense and therapeutic potentials in infectious diseases and cancer | |
| Hefazi et al. | Regulatory T cell therapy of graft-versus-host disease: advances and challenges | |
| Pieper et al. | Peripheral and Site‐Specific CD 4+ CD 28null T Cells from Rheumatoid Arthritis Patients Show Distinct Characteristics | |
| Koguchi et al. | Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8− thymocytes and invariant NKT cells but not in Treg cells | |
| EP2807250B1 (en) | Use of pdl1 expressing cells to convert t cells into regulatory t cells | |
| KR20210093908A (ko) | Ny-eso-1 t 세포 수용체 및 이의 사용 방법 | |
| JP2018524987A5 (enExample) | ||
| CN112888481A (zh) | 包含tnfr2结构域的新型car构建体 | |
| WO2013192215A1 (en) | Compositions and methods for diminishing an immune response | |
| Bernasconi et al. | Immune escape after hematopoietic stem cell transplantation (HSCT): from mechanisms to novel therapies | |
| Bachiller et al. | Natural killer cells in immunotherapy: are we nearly there? | |
| Käser et al. | Porcine regulatory T cells: mechanisms and T-cell targets of suppression | |
| Gramatica et al. | EZH2 inhibition mitigates HIV immune evasion, reduces reservoir formation, and promotes skewing of CD8+ T cells toward less-exhausted phenotypes | |
| Khoud et al. | Acute myeloid leukemia: is it T time? | |
| Lin et al. | Regulatory T cells in inflamed liver are dysfunctional in murine primary biliary cholangitis |